1-16 of 16
Paula R. Pohlmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P5-18-09: Halt-d: A randomized open label phase 2 study of crofelemer for the prevention of chemotherapy induced diarrhea (cid) in patients with breast cancer receiving trastuzumab, pertuzumab, and a taxane

Paula R Pohlmann, Deena Graham, Tianmin Wu, Yvonne Ottaviano, Mahsa Mohebtash, Shweta Kurian, Donna McNamara, Filipa Lynce, Robert Warren, Asma Dilawari, Suman Rao, Candace Mainor, Nicole Swanson, Ming Tan, Claudine Isaacs, Sandra M. Swain
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-18-09.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P5-18-09
Published: 15 February 2022
View article
Journal Articles

Abstract OT1-15-01: SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: HER2-mutated breast cancer cohort (ongoing clinical trial)

Alicia Okines, Paula R. Pohlmann, Jorge Ramos, Luke Walker, Erika Hamilton
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT1-15-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-OT1-15-01
Published: 15 February 2022
View article
Journal Articles

Abstract P4-02-10: Pfkfb3 inhibition significantly decreases endocrine-resistant breast cancer growth and induces necroptotic cell death

Brandon C Jones, Surojeet Sengupta, Catherine M Sevigny, Lu Jin, Paula R Pohlmann, Ayesha Shajahan-Haq, Robert Clarke
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-02-10.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P4-02-10
Published: 15 February 2022
View article
Journal Articles

Abstract CT218: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors

Manish R. Sharma, Richard D. Carvajal, Daniel Catenacci, Leisha A. Emens, Glenn J. Hanna, Dejan Juric, Yoon-Koo Kang, Jeeyun Lee, Keun-Wook Lee, Bob T. Li, Kathleen Moore, Mark D. Pegram, Paula R. Pohlmann, Drew Rasco, Alexander Spira, Arielle L. Heeke, Ding Wang, Lawrence Garbo, Sudhir Manda, Jasgit Sachdev, Shelley E. Ackerman, Heidi LeBlanc, David Dornan, Marcin Kowanetz, Michael N. Alonso, Amreen Husain, Edith A. Perez, Ecaterina Ileana Dumbrava
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT218.
DOI: https://doi.org/10.1158/1538-7445.AM2021-CT218
Published: 01 July 2021
View article
Journal Articles

Abstract 585: A robust method for expanding patient-derived circulating tumor cells ex vivo

Jerry Xiao, Joshua D. Kassner, Kelly Stanton, Richard Schlegel, Paula R. Pohlmann, Seema Agarwal
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 585.
DOI: https://doi.org/10.1158/1538-7445.AM2021-585
Published: 01 July 2021
View article
Journal Articles

Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Ecaterina Ileana Dumbrava, Manish R. Sharma, Richard D. Carvajal, Daniel Catenacci, Leisha A. Emens, Shirish M. Gadgeel, Glenn J. Hanna, Dejan Juric, Yoon-Koo Kang, Jeeyun Lee, Keun-Wook Lee, Bob T. Li, Kathleen Moore, Mark D. Pegram, Paula R. Pohlmann, Drew Rasco, Alexander Spira, Antoinette R. Tan, Shelley E. Ackerman, Heidi LeBlanc, David Dornan, Marcin Kowanetz, Michael N. Alonso, Edith A. Perez
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-03-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-OT-03-02
Published: 15 February 2021
View article
Journal Articles

Abstract PD3-08: Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status

Erika Hamilton, Mattea Reinisch, Sherene Loi, Alicia Okines, Paula R. Pohlmann, Eva Harder Brix, Hugues Bourgeois, Belinda Yeo, Cheryl Aylesworth, Melody Cobleigh, Anthony Goncalves, Rebecca Moroose, Katherine H.R. Tkaczuk, Michaela Tsai, Christine Simmons, Michael Andersson, Hatem Soliman, Michelina Cairo, Lisa A. Carey, David Cameron, Jorge Ramos, Wentao Feng, Mafalda Oliveira
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD3-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PD3-08
Published: 15 February 2021
View article
Journal Articles

Abstract PS4-02: The immune microenvironment of liver metastasis as a guide for immunotherapeutic potential in breast cancer

Sofi Castanon, Daniel Flores, Joanne Xiu, Paula R. Pohlmann, Foluso Ademuyiwa, Elia Obeid, Jasgit Sachdev, Michael Simon, Elisa Krill Jackson, Lee Schwartzberg, Antoinette R Tan, Neelima Denduluri, W. Michael Korn, Evanthia T Roussos Torres
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS4-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS4-02
Published: 15 February 2021
View article
Journal Articles

Abstract P4-09-05: Somatic genomic profiles of breast tumors differ by BRCA1 and BRCA2 variants of unknown significance status

Hadeel Assad, Isabel Hart, Kristen Purrington, Joanne Xiu, Paula R Pohlmann, Sandra Swain, Gregory Vidal, Michael Simon
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P4-09-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-P4-09-05
Published: 15 February 2020
View article
Journal Articles

Abstract P4-09-04: Prevalence of phosphatidylinositol-3-kinase (PI3K) pathway alterations and co-alteration of other markers in breast cancer

Katia Khoury, Antoinette Tan, Andrew Elliott, Joanne Xiu, Zoran Gatalica, Arielle L Heeke, Claudine Isaacs, Paula R Pohlmann, Lee S Schwartzberg, Michael Simon, Michael W Korn, Sandra M Swain, Filipa Lynce
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P4-09-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-P4-09-04
Published: 15 February 2020
View article
Journal Articles

Abstract P6-10-06: Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy

Paula R Pohlmann, Christina Yau, Angela DeMichele, Claudine Isaacs, Judy C Boughey, Nola Hylton, Michelle E Melisko, Jane Perlmutter, Hope S Rugo, W. Fraser Symmans, I-SPY 2 TRIAL Consortium, Donald A Berry, Laura Esserman
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P6-10-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-P6-10-06
Published: 15 February 2020
View article
Journal Articles

Abstract OT2-01-02: TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer

Rashmi K Murthy, Barbara J O'Brien, Ken R Hess, Nick Navin, Jason Johnson, Maria Gule-Monroe, Jose P Leone, Jennifer Specht, Michelle Melisko, Aki Morikawa, Anna M Storniolo, Adam Brufsky, Paula R Pohlmann, Deric M Park, Ben H Park, Ian Krop, Nancy U Lin, Antonio Wolff, Andres Forerro-Torres, Erica Stringer-Reasor
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): OT2-01-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-OT2-01-02
Published: 15 February 2020
View article
Journal Articles

Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer

Valerie M. Jansen, Neil E. Bhola, Joshua A. Bauer, Luigi Formisano, Kyung-Min Lee, Katherine E. Hutchinson, Agnieszka K. Witkiewicz, Preston D. Moore, Mónica Valéria Estrada, Violeta Sánchez, Paula G. Ericsson, Melinda E. Sanders, Paula R. Pohlmann, Michael J. Pishvaian, David A. Riddle, Teresa C. Dugger, Wenyi Wei, Erik S. Knudsen, Carlos L. Arteaga
Journal: Cancer Research
Cancer Res (2019) 79 (4): 874.
DOI: https://doi.org/10.1158/0008-5472.CAN-18-4086
Published: 15 February 2019
View article
PDF
Journal Articles

Abstract 907: Targeting glycolysis enzyme, PFKFB3, in endocrine therapy resistant breast cancers

Surojeet Sengupta, Catherine M. Sevigny, Xiaoyi Liu, Lu Jin, Paula R. Pohlmann, Robert Clarke
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 907.
DOI: https://doi.org/10.1158/1538-7445.AM2018-907
Published: 01 July 2018
View article
Journal Articles

Abstract CT028: Atezolizumab (atezo) + nab-paclitaxel (nab-pac) in metastatic triple-negative breast cancer (mTNBC): 2-year update from a ph Ib trial

Paula R. Pohlmann, Jennifer R. Diamond, Erika Hamilton, Sara M. Tolaney, Wei Zhang, Koho Iizuka, Paul Foster, Luciana Molinero, Roel Funke, Sylvia Adams
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT028.
DOI: https://doi.org/10.1158/1538-7445.AM2018-CT028
Published: 01 July 2018
View article
Journal Articles

Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer

Valerie M. Jansen, Neil E. Bhola, Joshua A. Bauer, Luigi Formisano, Kyung-Min Lee, Katherine E. Hutchinson, Agnieszka K. Witkiewicz, Preston D. Moore, Mónica Valéria Estrada, Violeta Sánchez, Paula G. Ericsson, Melinda E. Sanders, Paula R. Pohlmann, Michael J. Pishvaian, David A. Riddle, Teresa C. Dugger, Wenyi Wei, Erik S. Knudsen, Carlos L. Arteaga
Journal: Cancer Research
Cancer Res (2017) 77 (9): 2488–2499.
DOI: https://doi.org/10.1158/0008-5472.CAN-16-2653
Published: 30 April 2017
View article
PDF
Includes: Supplementary data